Regeneron Pharmaceuticals accused by US Justice Department of manipulating Medicare drug pricing for Eylea.
Regeneron Pharmaceuticals faces allegations from the US Justice Department for manipulating Medicare's drug pricing system by inflating the average sales price of its macular degeneration drug, Eylea. The lawsuit claims Regeneron failed to report substantial payments to drug distributors to subsidize Eylea's purchases, resulting in inflated Medicare costs. The company denies the allegations and will defend itself in court.
April 10, 2024
12 Articles